Pembrolizumab (Keytruda) was granted approval in 2014 for unresectable or metastatic melanoma and disease progression following ipilimumab and if found to have BRAF V600 mutation–positive disease, then a BRAF inhibitor is added to the regimen. The gene discussed is BRAF; the disease is metastatic melanoma.